{"id":62596,"date":"2026-04-24T12:56:12","date_gmt":"2026-04-24T10:56:12","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/04\/24\/syk-inhibition-limits-autoimmunity-and-abnormal-b-cell-phenotype-and-function-in-mice-with-b-cell-specific-traf3-deficiency\/"},"modified":"2026-04-24T12:56:12","modified_gmt":"2026-04-24T10:56:12","slug":"syk-inhibition-limits-autoimmunity-and-abnormal-b-cell-phenotype-and-function-in-mice-with-b-cell-specific-traf3-deficiency","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/04\/24\/syk-inhibition-limits-autoimmunity-and-abnormal-b-cell-phenotype-and-function-in-mice-with-b-cell-specific-traf3-deficiency\/","title":{"rendered":"Syk inhibition limits autoimmunity and abnormal B cell phenotype and function in mice with B cell-specific TRAF3 deficiency"},"content":{"rendered":"<div>\n<p><b>J Immunol<\/b>. 2026 Apr 15;215(4):vkag049. doi: 10.1093\/jimmun\/vkag049.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Autoimmune disorders reduce quality of life and lifespan and can increase B cell lymphoma risk. The adaptor protein TRAF3 regulates B cell survival, activation, and differentiation by restraining signaling through Toll-like receptors, tumor necrosis factor (TNF) receptor superfamily members, and the B cell antigen receptor-pathways linked to autoimmunity and lymphoma. Mice lacking TRAF3 in B cells (B-Traf3-\/-) develop both autoimmunity and B cell malignancies. TRAF3 negatively regulates activation of spleen tyrosine kinase (Syk), which is involved in multiple B cell signaling pathways. B-Traf3-\/- mice treated with the Food and Drug Administration (FDA)-approved Syk inhibitor Fostamatinib, exhibited reduction in autoantibodies, gland inflammation, and expansion of autoimmune-associated B cell populations. Fostamatinib also corrected enhanced pro-survival proteins and aberrant B cell survival in Traf3-\/- B cells, without inhibiting humoral responses to immunization. These findings identify elevated Syk activation as a key driver of B cell dysfunction and autoimmunity in B-Traf3-\/- mice, suggesting therapeutic potential for Syk inhibitors in conditions linked to decreased B cell TRAF3 levels.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42026764\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=2985117R&amp;ff=20260424065611&amp;v=2.19.0.post6+133c1fe\">42026764<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1093\/jimmun\/vkag049\">10.1093\/jimmun\/vkag049<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Immunol. 2026 Apr 15;215(4):vkag049. doi: 10.1093\/jimmun\/vkag049. ABSTRACT Autoimmune disorders reduce quality of life and lifespan and can increase B cell lymphoma risk. The adaptor protein TRAF3 regulates B cell survival, activation, and differentiation by restraining signaling through Toll-like receptors, tumor necrosis factor (TNF) receptor superfamily members, and the B cell antigen receptor-pathways linked to &#8230; <a title=\"Syk inhibition limits autoimmunity and abnormal B cell phenotype and function in mice with B cell-specific TRAF3 deficiency\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/24\/syk-inhibition-limits-autoimmunity-and-abnormal-b-cell-phenotype-and-function-in-mice-with-b-cell-specific-traf3-deficiency\/\" aria-label=\"Read more about Syk inhibition limits autoimmunity and abnormal B cell phenotype and function in mice with B cell-specific TRAF3 deficiency\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,71],"tags":[],"class_list":["post-62596","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-the-journal-of-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/62596","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=62596"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/62596\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=62596"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=62596"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=62596"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}